

# PMS2 gene

**Associated Syndrome Name: Lynch syndrome/Hereditary non-polyposis colorectal cancer (HNPCC)**

**PMS2 Summary Cancer Risk Table**

CANCER	GENETIC CANCER RISK
Colorectal	High Risk
Endometrial	High Risk
Gastric	Elevated Risk
Other	Elevated Risk
Ovarian	Elevated Risk
Pancreatic	Elevated Risk
Prostate	Elevated Risk
Skin	Elevated Risk

## PMS2 gene Overview

Lynch syndrome <sup>1, 2, 3, 4, 5, 6, 7, 8, 9</sup>

- Individuals with mutations in *PMS2* have Lynch syndrome. This condition is also known as hereditary non-polyposis colorectal cancer (HNPCC).
- Men and women with Lynch syndrome due to mutations in *PMS2* have a high risk of developing colorectal cancer, often at younger ages than seen in the general population. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome.
- Women with Lynch syndrome due to mutations in *PMS2* have a high risk for developing endometrial cancer and possibly an elevated risk for ovarian cancer, often at younger ages than typical in the general population.
- There is still some uncertainty as to whether patients with Lynch syndrome due to *PMS2* mutations have significantly increased risks for the wide variety of cancers associated with Lynch syndrome due to mutations in other genes. These cancers include small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, prostate, and pancreatic. In some cases, precise risk estimates are not available because there is less information available for patients with *PMS2* mutations compared with patients who have mutations in other Lynch syndrome genes. However, it is clear that the risks associated with *PMS2* mutations are not nearly as high as the risks seen with other Lynch syndrome genes.
- Cancer risks may be more significant in patients with a family history of particular cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
- Patients with Lynch syndrome due to mutations in *PMS2* may have an increased risk for gastric cancer. Earlier screening or more frequent intervals may be considered based on family history of upper gastrointestinal cancers or high-risk endoscopic findings. Random biopsy of the proximal and distal stomach should at minimum be performed on the initial upper endoscopy procedure to assess for *Helicobacter pylori*, autoimmune gastritis, and intestinal metaplasia.
- Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
- Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
- Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with a *PMS2* mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

## PMS2 gene Cancer Risk Table

CANCER TYPE	AGE RANGE	CANCER RISK	RISK FOR GENERAL POPULATION
Colorectal	To age 70 <sup>2, 3, 10, 11, 12</sup>	Up to 20%	1.8%
Endometrial	To age 70 <sup>1, 2, 3, 10, 12, 13, 14</sup>	12%-26%	1.9%
Overall cancer risk (Lynch cancers)	Risk for a second Lynch-related cancer after a first cancer diagnosis <sup>15, 16</sup>	Increased risk	NA
Prostate	To age 70 <sup>2, 3, 12, 14</sup>	Possibly elevated risk	6.3%
Ovarian	To age 70 <sup>2, 3, 12, 14</sup>	Possibly elevated risk	0.6%
Gastric	To age 70 <sup>3, 12</sup>	Possibly elevated risk	0.3%
Small Bowel	To age 70 <sup>3, 12, 13, 14</sup>	Possibly elevated risk	0.1%
Urothelial	To age 70 <sup>2, 3, 12</sup>	Possibly elevated risk	0.6%
Pancreatic	To age 70 <sup>12, 13</sup>	Possibly elevated risk	0.6%
Brain	To age 70 <sup>2, 3, 12, 14</sup>	Possibly elevated risk	0.4%
Hepatobiliary Tract	To age 70 <sup>3, 12, 13</sup>	Possibly elevated risk	0.5%
Lynch-associated Skin Tumors	To age 70 <sup>7, 10, 17, 18</sup>	Elevated risk	<1.0%

## PMS2 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines. The most recent version of each guideline should be consulted for more detailed and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient's personal medical history, surgeries and other treatments.

CANCER TYPE	PROCEDURE	AGE TO BEGIN	FREQUENCY (UNLESS OTHERWISE INDICATED BY FINDINGS)
Colorectal	Colonoscopy <sup>17</sup>	30 to 35 years, or 2 to 5 years younger than the earliest colorectal cancer diagnosis in the family if it is under age 30	Every 1 to 3 years
	Consider the use of aspirin as a risk-reduction agent <sup>17</sup>	Individualized	Individualized
Endometrial	Patient education about the importance of quickly seeking attention for endometrial cancer symptoms, such as abnormal bleeding or menstrual cycle irregularities <sup>17</sup>	Individualized	Individualized
	Consider pelvic examination, endometrial sampling and transvaginal ultrasound. <sup>17</sup>	30 to 35 years	Every 1 to 2 years
	Consider hysterectomy. <sup>17</sup>	After completion of childbearing	NA
Prostate	Incorporating information about increased risk due to gene mutation, start risk and benefit discussion about offering baseline digital rectal examination (DRE) and prostate specific antigen (PSA). <sup>17, 20</sup>	Age 40	Individualized, consider annually
Ovarian	Consider bilateral salpingo-oophorectomy. <sup>17</sup>	After completion of childbearing	NA

CANCER TYPE	PROCEDURE	AGE TO BEGIN	FREQUENCY (UNLESS OTHERWISE INDICATED BY FINDINGS)
	Consider transvaginal ultrasound and CA-125 measurement. <sup>17</sup>	30 to 35 years	NA
	Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives). <sup>17, 22</sup>	Individualized	NA
	Patient education about ovarian cancer symptoms <sup>17</sup>	Individualized	NA
Gastric	Consider testing and treating <i>Helicobacter pylori</i> infection. <sup>17</sup>	Individualized	NA
	Consider upper endoscopy, preferably performed in conjunction with colonoscopy. See clinical overview. <sup>17, 19</sup>	30 to 40 years, or earlier if there is a family history of gastric cancer at a young age	Every 2 to 4 years
Small Bowel	Consider upper endoscopy, preferably performed in conjunction with colonoscopy. Push enteroscopy can be considered in place of upper endoscopy to enhance small bowel visualization. <sup>17</sup>	30 to 40 years, or earlier if there is a family history of small bowel cancer at a young age	Every 2 to 4 years
Urothelial	Consider urinalysis. <sup>17</sup>	30 to 35 years	Annually
Pancreatic	Currently there are no specific medical management guidelines for the possibly increased risk for pancreatic cancer in mutation carriers.	NA	NA
Brain	Patient education about the importance of quickly seeking attention for signs and symptoms of neurologic cancer <sup>17</sup>	Individualized	NA
Hepatobiliary Tract	Currently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers. <sup>17</sup>	NA	NA
Lynch-associated Skin Tumors	Consider skin exams <sup>17</sup>	Individualized	Every 1 to 2 years
For Patients With A Cancer Diagnosis	For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., antibodies to PD-1) <sup>21</sup>	NA	NA

## Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the *PMS2* gene.

This patient's relatives are at risk for carrying the same mutation(s) and associated cancer risks as this patient. Cancer risks for females and males who have this/these mutation(s) are provided below.

Family members should talk to a healthcare provider about genetic testing. Close relatives such as parents, children, brothers and sisters have the highest chance of having the same mutation(s) as this patient. Other more distant relatives such as cousins, aunts, uncles, and grandparents also have a chance of carrying the same mutation(s). Testing of at-risk relatives can identify those family members with the same mutation(s) who may benefit from surveillance and early intervention.

In rare instances, an individual may inherit mutations in both copies of the *PMS2* gene, leading to the condition constitutional mismatch repair-deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a *PMS2* mutation. Screening the other biological parent of any children for *PMS2* mutations may be appropriate.<sup>7, 10</sup>

Parents who are concerned about the possibility of passing on a *PMS2* mutation to a future child may want to discuss options for

## References

1. Mu00f8ller P, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017 66:464-472. PMID: 26657901.
2. Dominguez-Valentin M, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med*. 2020 22:15-25. PMID: 31337882.
3. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, de la Chapelle A, Capella G, Clendenning M, Engel C, Gallinger S, Gomez Garcia E, Figueiredo JC, Haile R, Hampel HL, Hopper JL, Hoogerbrugge N, von Knebel Doeberitz M, Le Marchand L, Letteboer TGW, Jenkins MA, Lindblom A, Lindor NM, Mensenkamp AR, Mu00f8ller P, Newcomb PA, van Os TAM, Pearlman R, Pineda M, Rahner N, Redeker EJW, Olderode-Berends MJW, Rosty C, Schackert HK, Scott R, Senter L, Spruijt L, Steinke-Lange V, Suerink M, Thibodeau S, Vos YJ, Wagner A, Winship I, Hes FJ, Vasen HFA, Wijnen JT, Nielsen M, Win AK. Cancer Risks for *PMS2*-Associated Lynch Syndrome. *J Clin Oncol*. 2018 Oct 10;36(29):2961-2968. doi: 10.1200/JCO.2018.78.4777. Epub 2018 Aug 30. Erratum in: *J Clin Oncol*. 2019 Mar 20;37(9):761. PMID: 30161022; PMCID: PMC6349460.
4. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2014 23:437-49. PMID: 24425144.
5. Grindedal EM, et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2009 18:2460-7. PMID: 19723918.
6. Raymond VM, et al. Elevated risk of prostate cancer among men with Lynch syndrome. *J Clin Oncol*. 2013 31:1713-8. doi: 10.1200/JCO.2012.44.1238. Epub 2013 Mar 25. PMID: 23530095.
7. Kohlmann W, Gruber SB. Lynch Syndrome. 2018 Apr 12. In: Pagon RA, et al., editors. *GeneReviews*® [Internet]. PMID: 20301390.
8. Joost P, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of *MSH2* Mutations. *Urology*. 2015 86:1212-7. PMID: 26385421.
9. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA*. 2009 302:1790-5. PMID: 19861671.
10. Senter L, et al. The clinical phenotype of Lynch syndrome due to germline *PMS2* mutations. *Gastroenterology*. 2008 135:419-28. PMID: 18602922.
11. Suerink M, et al. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. *Genet Med*. 2019 21:2706-2712. PMID: 31204389.
12. SEER\*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. [Cited 2023 Mar 24]. Available from <https://seer.cancer.gov/explorer/>.
13. Mu00f8ller P, et al. Cancer risk and survival in path\_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2018 67:1306-1316. PMID: 28754778.
14. Vasen HF, et al. Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry. *Fam Cancer*. 2016 15:429-35. PMID: 26973060.
15. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. *J Natl Cancer Inst*. 2013 105:274-9. PMID: 23385444.
16. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. *J Natl Cancer Inst*. 2012 104:1363-72. PMID: 22933731.
17. Gupta S, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2023. May 30. Available at <https://www.nccn.org>.
18. ten Broeke SW, et al. Lynch syndrome caused by germline *PMS2* mutations: delineating the cancer risk. *J Clin Oncol*. 2015 33:319-25. PMID: 25512458.
19. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2023. Mar 10. Available at <https://www.nccn.org>.
20. Moses KA, et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2023. Jan 9. Available at <https://www.nccn.org>.

21. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/125514s031lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s031lbl.pdf)
22. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. V 3.2023. Feb 13. Available at <https://www.nccn.org>.

Last Updated on 31-Jan-2024